Not published · contact vendor
Primary-care and diagnostic settings
VERIFICATION IN PROGRESS
Cognoa’s Canvas Dx received first-of-its-kind FDA marketing authorization as an AI-based diagnosis aid for autism spectrum disorder in children 18 to 72 months, designed for use by clinicians including in primary care. Alongside eye-tracking systems like EarliPoint, it represents the emerging technology layer aimed at shortening the diagnostic bottleneck.
What is Cognoa (Canvas Dx)?
Cognoa (Canvas Dx) is fDA-authorized, AI-based diagnosis aid for autism in young children. It is listed in the Diagnostics & Assessment category of The ABA Index.
How much does Cognoa (Canvas Dx) cost?
Cognoa (Canvas Dx) does not publish pricing publicly — quotes come directly from the vendor. The ABA Index tracks pricing transparency for every listing and reports unpublished pricing as exactly that, never a guessed number.
Who is Cognoa (Canvas Dx) best for?
Based on its positioning and documented use: Primary-care and diagnostic settings.
What are alternatives to Cognoa (Canvas Dx)?
Other tools in the Diagnostics & Assessment category include ABLLS-R, ADOS-2, AFLS, As You Are. Each has an independent profile on The ABA Index.
ABLLS-R
Partington's criterion-referenced assessment of basic language and learner skills across 25 skill areas.
ADOS-2
The semi-structured, standardized diagnostic observation widely treated as the gold standard in autism evaluation.
AFLS
Assessment of Functional Living Skills — practical independence skills across home, school, and community.
As You Are
Virtual clinic providing telehealth autism diagnostic evaluations for children.
See something outdated or wrong? This profile is maintained independently — vendors and users can request corrections and we verify against primary sources.
Request a correction